Ensysce Biosciences (ENSC) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38306
Entity Registrant Name	Ensysce Biosciences, Inc.
Entity Central Index Key	0001716947
Entity Tax Identification Number	82-2755287
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		2,841,091
Common Stock, $0.0001 par value per share
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ENSC
Security Exchange Name	NASDAQ
Warrants to purchase one share of Common Stock
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	ENSCW

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,503,081	$ 12,264,736
Unbilled receivable	140,813	441,721
Right-of-use asset	35,313	24,721
Prepaid expenses and other current assets	2,983,071	2,931,415
Total current assets	7,662,278	15,662,593
Property and equipment, net
Other assets	627,550	754,756
Total assets	8,289,828	16,417,349
Current liabilities:
Accounts payable	1,285,514	301,104
Accrued expenses and other liabilities	2,236,273	3,407,533
Payable to related parties	800,000
Lease liability	35,403	24,874
Notes payable and accrued interest ($7,199,135 and $12,358,886 at fair value at September 30, 2022 and December 31, 2021, respectively)	7,552,774	12,748,155
Total current liabilities	11,909,964	16,481,666
Long-term liabilities:
Notes payable, net of current portion (at fair value)	1,386,967	4,440,951
Other long-term liabilities	1,414,829	3,652,790
Total long-term liabilities	2,801,796	8,093,741
Total liabilities	14,711,760	24,575,407
Commitments and contingencies (Note 6)
Stockholders’ deficit
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 250,000,000 and 150,000,000 shares authorized at September 30, 2022 and December 31, 2021; 2,208,446 and 1,233,148 shares issued at September 30, 2022 (unaudited) and December 31, 2021, respectively; 2,207,458 and 1,232,160 shares outstanding at September 30, 2022 (unaudited) and December 31, 2021, respectively	221	124
Additional paid-in capital	99,314,436	77,967,200
Accumulated deficit	(105,409,155)	(85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ deficit	(6,094,498)	(7,878,243)
Noncontrolling interests in stockholders’ deficit	(327,434)	(279,815)
Total stockholders’ deficit	(6,421,932)	(8,158,058)
Total liabilities and stockholders’ deficit	$ 8,289,828	$ 16,417,349

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Notes payable and accrued interest	$ 7,199,135	$ 12,358,886
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	150,000,000
Common stock, shares issued	2,208,446	1,233,148
Common stock, shares outstanding	2,207,458	1,232,160

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Federal grants	$ 279,351	$ 1,200,816	$ 1,089,920	$ 1,895,907
Operating expenses:
Research and development	4,756,096	1,714,635	13,393,948	2,502,232
General and administrative	1,686,580	16,372,976	5,717,281	17,257,361
Total operating expenses	6,442,676	18,087,611	19,111,229	19,759,593
Loss from operations	(6,163,325)	(16,886,795)	(18,021,309)	(17,863,686)
Other income (expense):
Issuance costs for convertible notes	(1,118,721)	(500,158)	(1,118,721)	(500,158)
Change in fair value of derivative liabilities				673,314
Loss on issuance of convertible notes	(3,609,944)		(3,609,944)
Change in fair value of convertible notes	3,491,513	1,071,099	6,169,929	1,071,099
Issuance of liability classified warrants	(3,737,371)	(1,325,804)	(3,737,371)	(1,325,804)
Change in fair value of liability classified warrants	2,683,340	405,086	5,626,130	405,086
Loss on debt conversions	(1,404,877)		(4,000,155)
Interest expense	(4,859)	(24,660)	(57,662)	(1,282,820)
Loss on extinguishment of debt				(347,566)
Other income and expense, net	8,679	61,758	19,494	61,758
Total other income (expense), net	(3,692,240)	(312,679)	(708,300)	(1,245,091)
Net loss	(9,855,565)	(17,199,474)	(18,729,609)	(19,108,777)
Net loss attributable to noncontrolling interests	(21,492)	(35,948)	(47,619)	(61,976)
Deemed dividend related to warrants down round provision	63,539		881,598
Net loss attributable to common stockholders	$ (9,897,612)	$ (17,163,526)	$ (19,563,588)	$ (19,046,801)
Net loss per share:
Net loss per share attributable to common stockholders, basic and diluted	$ (5.13)	$ (14.15)	$ (11.74)	$ (20.31)
Weighted average common shares outstanding, basic and diluted	1,928,727	1,212,791	1,666,253	937,764

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Common Stock [Member] Previously Reported [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Previously Reported [Member]	Retained Earnings [Member]	Retained Earnings [Member] Previously Reported [Member]	Noncontrolling Interest [Member]	Noncontrolling Interest [Member] Previously Reported [Member]	Total	Previously Reported [Member]
Beginning balance, value at Dec. 31, 2019		$ 300		$ 49,517,614		$ (55,958,716)		$ (217,625)		$ (6,658,427)
Beginning balance, shares at Dec. 31, 2019		11,973,258
Retroactive application of recapitalization		$ (220)		$ 220
Retroactive application of recapitalization, shares		(11,184,821)
Ending balance, value at Dec. 31, 2020	$ 80		$ 49,517,834		$ (55,958,716)		$ (217,625)		$ (6,658,427)
Ending balance, shares at Dec. 31, 2020	788,437
Stock-based compensation			105,026						105,026
Issuance of warrants			11,565,472						11,565,472
Warrants modification			56,590						56,590
Net loss					(19,046,801)		(61,976)		(19,108,777)
Conversions of convertible notes	$ 7		5,696,696						5,696,703
Conversions of convertible notes, shares	67,899
Exercise of stock options	$ 1		262,861						262,862
Exercise of stock options, shares	14,241
Issuance of common stock for business combination, net of transaction costs	$ 34		7,695,230						7,695,264
Issuance of common stock for business combination, net of transaction costs, shares	342,214
Ending balance, value at Sep. 30, 2021	$ 122		74,899,709		(75,005,517)		(279,601)		(385,287)
Ending balance, shares at Sep. 30, 2021	1,212,791
Beginning balance, value at Jun. 30, 2021	$ 122		63,252,814		(57,841,991)		(243,653)		5,167,292
Beginning balance, shares at Jun. 30, 2021	1,212,791
Stock-based compensation			24,833						24,833
Issuance of warrants			11,565,472						11,565,472
Warrants modification			56,590						56,590
Net loss					(17,163,526)		(35,948)		(17,199,474)
Ending balance, value at Sep. 30, 2021	$ 122		74,899,709		(75,005,517)		(279,601)		(385,287)
Ending balance, shares at Sep. 30, 2021	1,212,791
Beginning balance, value at Dec. 31, 2021	$ 124		77,967,200		(85,845,567)		(279,815)		(8,158,058)
Beginning balance, shares at Dec. 31, 2021	1,232,160
Stock-based compensation			2,543,388						2,543,388
Net loss					(18,681,990)		(47,619)		(18,729,609)
Conversions of convertible notes	$ 93		17,868,004						17,868,097
Conversions of convertible notes, shares	937,924
Settlement of restricted stock units	$ 4		(4)
Settlement of restricted stock units, shares	34,867
Deemed dividend related to warrants down round provision			881,598		(881,598)
Exercise of stock options, shares
Consultant compensation			54,250						$ 54,250
Consultant compensation, shares	2,507
Ending balance, value at Sep. 30, 2022	$ 221		99,314,436		(105,409,155)		(327,434)		(6,421,932)
Ending balance, shares at Sep. 30, 2022	2,207,458
Beginning balance, value at Jun. 30, 2022	$ 178		95,019,729		(95,511,543)		(305,942)		(797,578)
Beginning balance, shares at Jun. 30, 2022	1,776,520
Stock-based compensation			157,148						157,148
Net loss					(9,834,073)		(21,492)		(9,855,565)
Conversions of convertible notes	$ 43		4,074,020						4,074,063
Conversions of convertible notes, shares	428,438
Settlement of restricted stock units
Settlement of restricted stock units, shares	2,500
Deemed dividend related to warrants down round provision			63,539		(63,539)
Ending balance, value at Sep. 30, 2022	$ 221		$ 99,314,436		$ (105,409,155)		$ (327,434)		$ (6,421,932)
Ending balance, shares at Sep. 30, 2022	2,207,458

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (9,855,565)	$ (17,199,474)	$ (18,729,609)	$ (19,108,777)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		50		151
Gain on sale of asset			(4,500)
Accrued interest			57,536	336,851
Accretion of discounts on promissory notes				945,969
Change in fair value of derivative liabilities				(673,314)
Change in fair value of liability classified warrants			(5,626,130)
Loss on issuance of convertible notes	3,609,944		3,609,944
Change in fair value of convertible notes			(6,169,929)	(1,071,099)
Loss on extinguishment of debt				347,566
Stock-based compensation			855,160	105,026
Issuance of warrants for share subscription facility				11,565,472
Issuance of liability classified warrants			3,737,371	620,718
Issuance costs for convertible notes			946,085	800,158
Commitment fee for share subscription facility				1,124,292
Warrant modification				56,590
Lease cost			(63)	(1,838)
Loss on debt conversions	1,404,877		4,000,155
Changes in operating assets and liabilities:
Unbilled receivable			300,908	(86,867)
Prepaid expenses and other assets			475,499	(683,492)
Accounts payable			984,410	(1,252,740)
Accrued expenses and other liabilities			971,344	2,500,970
Net cash used in operating activities			(14,591,819)	(4,474,364)
Cash flows from investing activities:
Proceeds from sale of asset			4,500
Net cash provided by investing activities			4,500
Cash flows from financing activities:
Proceeds from issuance of convertible notes, net			7,533,915	4,549,842
Proceeds from issuance of promissory notes to related parties				350,000
Proceeds from exercise of stock options				262,862
Repayment of promissory notes				(467,774)
Repayments of convertible notes			(265,812)
Proceeds from issuance of common stock for business combination, net of transaction costs				6,626,312
Repayment of financed insurance premiums			(442,439)	(195,420)
Net cash (used in) provided by financing activities			6,825,664	11,125,822
Increase in cash and cash equivalents			(7,761,655)	6,651,458
Cash and cash equivalents beginning of period			12,264,736	194,214	$ 194,214
Cash and cash equivalents end of period	$ 4,503,081	$ 6,845,672	4,503,081	6,845,672	12,264,736
Supplemental cash flow information:
Income tax payments			1,600	1,600
Supplemental disclosure of non-cash investing and financing activities:
Stock-based compensation			1,742,478
Conversions of convertible notes and accrued interest into common stock			13,879,535	5,696,703
Payable to related parties			800,000
Net assets acquired in business combination				1,068,950
Financed insurance premiums			399,949	867,300	$ 900,000
Share subscription facility transaction costs				12,689,764
Deemed dividend related to warrants down round provision			$ 881,598

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, EBIR, Inc. (“EBIR”, formerly Covistat, Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is developing abuse and overdose resistant pain drugs, with a clinical stage program for the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR TM TM On January 31, 2021, LACQ entered into the Merger Agreement with Former Ensysce and Merger Sub. Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly-owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $ 0.0001 On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing. In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of 0.06585 71.8 In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, Covistat, Inc., a Delaware corporation. Pursuant to the articles of incorporation, Covistat was authorized to issue 1,000,000 0.001 100,000 0.001 79.2 19.8 1.0 The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three and nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022. Reverse Stock Split In October 2022, the Company completed a 1-for-20 reverse split Business Combination The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $ 7.8 1.1 0.06585 Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue and had an accumulated deficit of $ 105.4 In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $ 60.0 55,306 200.20 1.2 0.8 million 0.4 million 0.8 million 0.4 million In September 2021, the Company entered into a $ 15.9 8.48 The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, warrants, options to purchase the Company’s common stock, and the notes payable. Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss. Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No 50 151 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three and nine months ended September 30, 2022 and 2021. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet. Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of September 30, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes with a face value of $ 15.9 2022 Notes In July 2022 the Company issued convertible notes with a face value of $ 8.5 Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of September 30, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 September 30, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible notes $ 8,586,102 $ - $ - $ 8,586,102 Liability classified warrants 1,414,829 - - 1,414,829 Total $ 10,000,931 $ - $ - $ 10,000,931 Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions (14,133,750 ) (14,133,750 ) - Change in fair value (8,186,115 ) (2,559,985 ) (5,626,130 ) Fair value, September 30, 2022 $ 10,000,931 $ 8,586,102 $ 1,414,829 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.8 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Three Months Ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 MPAR $ 206,290 $ 1,119,312 $ 710,761 $ 1,246,424 OUD 73,061 81,504 379,159 649,483 Total $ 279,351 $ 1,200,816 $ 1,089,920 $ 1,895,907 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded. Immaterial Correction of an Error Adjusted in Prior Quarter In August 2022, the Company concluded that due to an error in the measurement of the unbilled receivable and the associated grant revenue as of December 31, 2021, and March 31, 2022, the June 30, 2022, balance sheet would be adjusted. The change resulted in a decrease in the balance of the unbilled receivable of $ 214,308 The Company, in consultation with the Audit Committee of the Board of Directors, evaluated the effect of these adjustments on the Company’s consolidated financial statements under ASC 250, Accounting Changes and Error Corrections and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and determined it was not necessary to recall its previously issued consolidated financial statements as the errors did not materially misstate any previously issued consolidated financial statements and the correction of the error in the current fiscal year is also not material. The Company looked at both quantitative and qualitative characteristics of the required corrections in making the determination. Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three and nine months ended September 30, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (9,897,612 ) $ (17,163,526 ) $ (19,563,588 ) $ (19,046,801 ) Denominator: Weighted average shares outstanding, basic and diluted 1,928,727 1,212,791 1,666,253 937,764 Net loss per share attributable to common stockholders, basic and diluted $ (5.13 ) $ (14.15 ) $ (11.74 ) $ (20.31 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options 350,995 222,203 328,538 225,833 Warrants 1,054,544 1,000,953 1,054,544 335,531 Total 1,405,539 1,223,156 1,383,082 561,364 Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and the adoption did not have a significant impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (A Consensus of the FASB Emerging Issues Task Force (the “EITF”)) – to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. Under the amendments, an issuer should measure the effect of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before modification. The EITF concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. On January 1, 2022, the Company adopted ASU 2021-04 and the adoption did not have a significant impact on the consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, December 31, 2022 2021 Prepaid research and development $ 2,323,473 $ 2,124,008 Prepaid insurance 550,634 733,234 Other prepaid expenses 108,964 74,173 Total prepaid expenses and other current assets $ 2,983,071 $ 2,931,415

ACCRUED EXPENSES AND OTHER LIAB

ACCRUED EXPENSES AND OTHER LIABILITIES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES September 30, December 31, 2022 2021 Share subscription facility commitment fees $ 400,000 $ 800,000 Accrued research and development 1,186,498 388,997 Bonus accrual 297,224 610,000 Professional fees 203,034 138,086 Accrued scientific advisory board fees 60,032 60,032 Consultant stock compensation expenses - 1,342,479 Other accrued liabilities 89,485 67,939 Total accrued expenses and other liabilities $ 2,236,273 $ 3,407,533 Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES September 30, December 31, 2022 2021 Share subscription facility commitment fees $ - $ 349,202 Liability classified warrants 1,414,829 3,303,588 Total other long-term liabilities $ 1,414,829 $ 3,652,790

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 – COMMITMENTS AND CONTINGENCIES Purchase Commitments As of September 30, 2022, the Company’s commitments included an estimated $ 25.7 Litigation As of September 30, 2022 and December 31, 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Lease In August 2020, the Company entered into an agreement to lease office space. The original lease commencement date was October 1, 2020 and was subsequently amended to extend the term of the lease through October 31, 2023 with no option to renew. The amendment resulted in a modification of the lease under ASC 842 and the Company remeasured the lease liability as of the amendment date. As of September 30, 2022, the future lease payments totaled $ 35,403 The Company recognized total rent expense of $ 7,939 23,606 11,781 36,058 Compensation Subject to Shareholder Approval In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase 25,000 125.60 2,500 10,000 one year 50 1,342,479

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE The following table provides a summary of the Company’s outstanding debt as of September 30, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair Value Adjustment Net debt balance 2021 Notes $ 379,695 $ 11,006 $ - $ 390,701 2022 Notes 8,126,667 93,559 (24,825 ) 8,195,401 Financed Insurance 348,780 4,859 - 353,639 Total $ 8,855,142 $ 109,424 $ (24,825 ) $ 8,939,741 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Fair value adjustment Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Financed Insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106 The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Three months ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Stated interest accrual $ 4,859 $ 24,660 $ 6,864 $ 251,857 Debt discount amortization - - - 945,969 Total $ 4,859 $ 24,660 $ 6,864 $ 1,197,826 2021 Notes On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provided for two closings: the first closing for $ 5.3 4.6 10.6 9.4 The proceeds of the 2021 Notes shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders. The 2021 Notes mature on June 23, 2023 August 4, 2023 5 6 The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $ 15.9 million. The Company recorded total issuance costs of $ 1.9 million representing investment banking and legal fees of $ 1.0 million and original issue discounts of $ 0.9 million. After multiple conversions (at original contract terms and at amended reduced conversion prices) since issuance, the Company reflected the remaining balance due as of September 30, 2022 and recognized a change in fair value of convertible notes of $ 45,329 (loss) for the three-month period then ended and a change in fair value of convertible notes of $ 2.7 million (gain) for the nine-month period ended September 30, 2022 primarily due to reductions in the Company’s stock price. The September 30, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8 % cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the amount of interest expense after consideration of the conversions would be $ 39,847 and $ 0.2 The 2021 Notes may be converted into the Company’s common stock at the option of the holder in whole or in part at the conversion price of $ 117.40 beneficial ownership limitation of 4.99% At the Company’s option, the Company may redeem some or all of the then-outstanding principal amount of the 2021 Notes for cash in an amount equal to 100% of the principal to be redeemed, plus accrued but unpaid interest, plus all other amounts due with respect to the 2021 Notes. Beginning January 1, 2022 for the First Closing, and February 1, 2022 for the Second Closing, and the first of each subsequent month, terminating upon the full redemption of the 2021 Notes (each a “Monthly Redemption Date”), the Company shall redeem the Monthly Redemption Amount (defined below), payable in cash or shares. The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $ 117.40 92 15.60 15.60 265,812 The Monthly Redemption Amount is defined as 1/18 th If, at any time while the 2021 Notes are outstanding, the Company carries out one or more capital raises in excess of $ 5.0 20 The following table provides a summary of the Company’s 2021 note conversions during the nine-month period ending September 30, 2022: SCHEDULE OF CONVERSION DEBT Three Months Ended Shares Weighted Average Conversion Value March 31, 2022 235,428 $ 27.07 $ 6,372,700 June 30, 2022 274,058 $ 17.61 4,826,053 September 30, 2022 339,854 $ 6.84 2,323,081 Total 849,340 $ 13,521,834 On August 8, 2022, the parties agreed to modify the conversion price of the remaining 2021 Notes from $ 15.60 7.00 7.00 4.60 1.4 4.0 million 1.0 2022 Notes On June 30, 2022, the Company entered into an $ 8.0 4.24 4.0 On the issuance date, the Company assessed the probability of the potential settlement scenarios under the terms of the 2022 Notes and determined that the predominant settlement feature of the 2022 Notes was the redemption feature into shares of the Company’s common stock issuable at the lower of the conversion price or 92% of the average of the three lowest VWAPs in the 10 trading days immediately preceding the redemption date. As the predominant settlement feature of the 2022 Notes is to settle a fixed monetary amount into a variable number of shares, the 2022 Notes fell within the scope of ASC 480. Accordingly, the Company determined that the 2022 Notes should be recorded at estimated fair value on its issuance date and adjusted to its estimated fair value as of each reporting date with the change in estimated fair value recorded as a component other income (expense) in the Company’s consolidated statements of operations. The Company recorded the 2022 Notes at an initial fair value of $ 12.06 3.6 1.1 6% 0.5 0.6 3.5 The September 30, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8% cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the amount of interest expense after consideration of the conversions would be $ 0.1 The 2022 Notes are convertible into common stock, at a per share conversion price equal to $ 10.90 10 th The Company may elect to pay all or part of the redemption amount in cash with a premium of eight percent or in conversion shares of common stock based on a conversion price equal to the lesser of (i) the conversion price and (ii) 92% of the average of the three lowest VWAPs (as defined) during the ten consecutive trading days ending on the trading day that is immediately prior to the applicable redemption date, but in no event may the Company pay the redemption amount in conversion shares of common stock unless the conversion price is at least equal to $2.006 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder. In connection with each of the first and second closings of the 2022 Notes the Company also issued warrants to purchase 233,395 14.17 30 five 15.60 The proceeds of the 2022 Notes will be used for working capital purposes subject to certain customary restrictions are secured by the Company’s rights to its patents and licenses. The Company is restricted from issuing certain additional debt or equity without the prior written consent of the holders for certain specified periods set forth in the 2022 Notes. If, at any time while the 2022 Notes are outstanding, the Company carries out one or more capital raises in excess of $ 5.0 20 The 2022 Notes mature on December 29, 2023 February 7, 2024 6 6 The following table provides a summary of the Company’s 2022 Notes conversions during the nine-month period ending September 30, 2022: SCHEDULE OF CONVERSION DEBT Three Months Ended Shares Weighted Average Conversion Price Conversion Value September 30, 2022 88,584 $ 4.04 $ 357,701 Total 88,584 $ 357,701 Financed insurance premiums During year ended December 31, 2021, the Company financed its directors’ and officers’ liability insurance in the amount of $ 0.9 0.4 4,589 6,684

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 1,500,000 0.0001 250,000,000 no Common Stock On June 30, 2021, in connection with the Closing, the following common stock activity occurred: ● 802,679 ● 310,963 ● 67,899 5.8 ● 988 ● 25,000 ● 6,250 Warrants On September 30, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 945,063 $ 200.00 230.00 LACQ warrants Equity (b) 55,306 $ 4.04 Share subscription facility Equity (c) 18,058 $ 15.60 2021 Notes Liability (d) 36,116 $ 15.60 2021 Notes Liability (e) 233,394 $ 14.17 2022 Notes Liability (f) 233,394 $ 14.17 2022 Notes Liability 1,521,331 a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 945,063 200.00 230.00 June 30, 2026 500,000 445,063 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 25,000 230.00 200.00 56,590 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 55,306 three 200.20 289.80 11.6 On December 28, 2021, January 3, 2022, February 1, 2022, March 1, 2022, May 2, 2022,June 1, 2022, July 1, 2022, August 10, 2022, September 20, 2022 and September 29, 2022 the exercise price of the warrants adjusted to $ 90.00 56.60 31.60 19.20 18.80 9.20 8.00 7.00 4.60 4.00 c) On September 24, 2021, the Company issued 18,058 152.60 September 23, 2026 15.60 d) On November 5, 2021, the Company issued 36,116 152.60 November 4, 2026 15.60 e) On July 1, 2022, the Company issued 233,394 14.17 June 29, 2027 f) On August 9, 2022, the Company issued 233,394 14.17 August 8, 2027 The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (a) LACQ (b) Share (b) Share Stock price $ 289.80 $289.80 $ 4.80 85.80 Exercise price $ 200.00 230.00 $200.20 $ 4.00 90.00 Expected term (years) 3.00 3.00 1.76 2.49 Volatility 110.0 % 110.0 108.2 125.3 Risk free rate 0.5 % 0.5 1.0 4.2 (c) Liability (c) Liability (d) Liability (d) Liability Stock price $ 89.80 $ 4.30 $ 45.00 $ 4.30 Exercise price $ 152.60 $ 15.60 $ 152.60 $ 15.60 Expected term (years) 5.00 4.00 5.00 4.10 Volatility 94.1 % 116.1 % 94.1 % 114.9 % Risk free rate 1.0 % 4.1 % 1.0 % 4.1 % (e) Liability (e) Liability (f) Liability (f) Liability Stock price $ 11.40 $ 4.40 $ 10.60 $ 4.40 Exercise price $ 14.20 $ 14.20 $ 14.20 $ 14.20 Expected term (years) 5.00 4.75 5.00 4.86 Volatility 98.9 % 109.4 % 102.8 % 108.3 % Risk free rate 2.9 % 4.1 % 3.0 % 4.1 %

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 - STOCK-BASED COMPENSATION In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants. In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options. In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024. In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 221,191 50,000 150,000 The Company recognized within general and administrative expense stock-based compensation expense of $ 128,357 731,126 24,833 105,026 28,791 124,034 no Option Activity During the nine months ended September 30, 2022, the Company granted stock options to purchase an aggregate of 114,550 zero 4 8.50 125.60 The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining Intrinsic value Outstanding at December 31, 2021 222,191 $ 48.00 6.00 $ 10,207,306 Granted 114,550 77.30 7.63 - Exercised - - - - Expired / Forfeited (10,000 ) 21.40 - - Outstanding at September 30, 2022 326,741 59.13 6.57 - Exercisable at September 30, 2022 284,014 62.03 6.15 - Vested and expected to vest 326,741 59.13 6.57 - Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Nine Months Ended September 30, 2022 Stock price $ 8.60 34.00 Exercise price $ 8.5 125.60 Expected stock price volatility 76.61 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52 3.14 % Expected dividend yield 0 % ● Expected stock-price volatility. ● Expected term. ● Risk-free interest rate. ● Expected dividend yield. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2022 was $ 19.24 As of September 30, 2022, the Company had an aggregate of $ 605,868 1.42 Restricted Stock Units The following table summarizes the Company’s restricted stock units activity during the nine months ended September 30, 2022: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weight average fair value Outstanding at December 31, 2021 - $ - Granted 61,367 23.02 Released (34,867 ) 26.25 Cancelled (10,000 ) - Outstanding at September 30, 2022 16,500 10.63 The remaining awards outstanding are subject to time-based vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date. Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE September 30, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 343,241 Awards available for future grant under 2021 Omnibus Incentive Plan 44,095 2022 Notes outstanding 754,149 Warrants outstanding 1,521,331 Total shares of common stock reserved for future issuance 2,662,816

RELATED PARTIES

RELATED PARTIES	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 10 - RELATED PARTIES The Company paid cash compensation during the three and nine months ended September 30, 2021 of $ 3,584 and $ 43,898 , respectively, to the Chief Executive Officer through a separate operating company with which the Chief Executive Officer is affiliated. There were no such payments in the three and nine months ended September 30, 2022. In July 2022, the Chief Executive Officer and a Board member transferred 46,062 shares of registered common stock to GYBL to settle $ 0.8 million of Company obligations related to the GEM Agreement (Note 2). In October 2022, 46,062 shares of unregistered and restricted common stock were subsequently issued by the Company to the related parties as reimbursement.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 - SUBSEQUENT EVENTS On October 11, 2022, the Company paid $ 390,701 On October 28, 2022, the Company completed a 1-for-20 reverse split In the fourth quarter of 2022, the Company issued 573,944 2.1

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, warrants, options to purchase the Company’s common stock, and the notes payable.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.
Property and Equipment	Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No 50 151 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three and nine months ended September 30, 2022 and 2021.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.
Fair Value Measurement	Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of September 30, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes with a face value of $ 15.9 2022 Notes In July 2022 the Company issued convertible notes with a face value of $ 8.5 Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of September 30, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 September 30, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible notes $ 8,586,102 $ - $ - $ 8,586,102 Liability classified warrants 1,414,829 - - 1,414,829 Total $ 10,000,931 $ - $ - $ 10,000,931 Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions (14,133,750 ) (14,133,750 ) - Change in fair value (8,186,115 ) (2,559,985 ) (5,626,130 ) Fair value, September 30, 2022 $ 10,000,931 $ 8,586,102 $ 1,414,829
Federal Grants	Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.8 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Three Months Ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 MPAR $ 206,290 $ 1,119,312 $ 710,761 $ 1,246,424 OUD 73,061 81,504 379,159 649,483 Total $ 279,351 $ 1,200,816 $ 1,089,920 $ 1,895,907 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.
Immaterial Correction of an Error Adjusted in Prior Quarter	Immaterial Correction of an Error Adjusted in Prior Quarter In August 2022, the Company concluded that due to an error in the measurement of the unbilled receivable and the associated grant revenue as of December 31, 2021, and March 31, 2022, the June 30, 2022, balance sheet would be adjusted. The change resulted in a decrease in the balance of the unbilled receivable of $ 214,308 The Company, in consultation with the Audit Committee of the Board of Directors, evaluated the effect of these adjustments on the Company’s consolidated financial statements under ASC 250, Accounting Changes and Error Corrections and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and determined it was not necessary to recall its previously issued consolidated financial statements as the errors did not materially misstate any previously issued consolidated financial statements and the correction of the error in the current fiscal year is also not material. The Company looked at both quantitative and qualitative characteristics of the required corrections in making the determination.
Research and Development Costs	Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based Compensation	Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three and nine months ended September 30, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.
Income Taxes	Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Earnings per Share	Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (9,897,612 ) $ (17,163,526 ) $ (19,563,588 ) $ (19,046,801 ) Denominator: Weighted average shares outstanding, basic and diluted 1,928,727 1,212,791 1,666,253 937,764 Net loss per share attributable to common stockholders, basic and diluted $ (5.13 ) $ (14.15 ) $ (11.74 ) $ (20.31 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options 350,995 222,203 328,538 225,833 Warrants 1,054,544 1,000,953 1,054,544 335,531 Total 1,405,539 1,223,156 1,383,082 561,364
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and the adoption did not have a significant impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (A Consensus of the FASB Emerging Issues Task Force (the “EITF”)) – to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. Under the amendments, an issuer should measure the effect of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before modification. The EITF concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. On January 1, 2022, the Company adopted ASU 2021-04 and the adoption did not have a significant impact on the consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of September 30, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 September 30, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible notes $ 8,586,102 $ - $ - $ 8,586,102 Liability classified warrants 1,414,829 - - 1,414,829 Total $ 10,000,931 $ - $ - $ 10,000,931 Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3	The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions (14,133,750 ) (14,133,750 ) - Change in fair value (8,186,115 ) (2,559,985 ) (5,626,130 ) Fair value, September 30, 2022 $ 10,000,931 $ 8,586,102 $ 1,414,829
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS	The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Three Months Ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 MPAR $ 206,290 $ 1,119,312 $ 710,761 $ 1,246,424 OUD 73,061 81,504 379,159 649,483 Total $ 279,351 $ 1,200,816 $ 1,089,920 $ 1,895,907
SCHEDULE OF EARNINGS PER SHARE RECONCILIATION	SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (9,897,612 ) $ (17,163,526 ) $ (19,563,588 ) $ (19,046,801 ) Denominator: Weighted average shares outstanding, basic and diluted 1,928,727 1,212,791 1,666,253 937,764 Net loss per share attributable to common stockholders, basic and diluted $ (5.13 ) $ (14.15 ) $ (11.74 ) $ (20.31 )
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES	The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options 350,995 222,203 328,538 225,833 Warrants 1,054,544 1,000,953 1,054,544 335,531 Total 1,405,539 1,223,156 1,383,082 561,364

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, December 31, 2022 2021 Prepaid research and development $ 2,323,473 $ 2,124,008 Prepaid insurance 550,634 733,234 Other prepaid expenses 108,964 74,173 Total prepaid expenses and other current assets $ 2,983,071 $ 2,931,415

ACCRUED EXPENSES AND OTHER LI_2

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES	Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES September 30, December 31, 2022 2021 Share subscription facility commitment fees $ 400,000 $ 800,000 Accrued research and development 1,186,498 388,997 Bonus accrual 297,224 610,000 Professional fees 203,034 138,086 Accrued scientific advisory board fees 60,032 60,032 Consultant stock compensation expenses - 1,342,479 Other accrued liabilities 89,485 67,939 Total accrued expenses and other liabilities $ 2,236,273 $ 3,407,533
SCHEDULE OF OTHER LONG-TERM LIABILITIES	Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES September 30, December 31, 2022 2021 Share subscription facility commitment fees $ - $ 349,202 Liability classified warrants 1,414,829 3,303,588 Total other long-term liabilities $ 1,414,829 $ 3,652,790

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2022
Short-Term Debt [Line Items]
SCHEDULE OF DEBT	The following table provides a summary of the Company’s outstanding debt as of September 30, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair Value Adjustment Net debt balance 2021 Notes $ 379,695 $ 11,006 $ - $ 390,701 2022 Notes 8,126,667 93,559 (24,825 ) 8,195,401 Financed Insurance 348,780 4,859 - 353,639 Total $ 8,855,142 $ 109,424 $ (24,825 ) $ 8,939,741 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Fair value adjustment Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Financed Insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106
SCHEDULE OF INTEREST EXPENSE DEBT	The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Three months ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Stated interest accrual $ 4,859 $ 24,660 $ 6,864 $ 251,857 Debt discount amortization - - - 945,969 Total $ 4,859 $ 24,660 $ 6,864 $ 1,197,826
SCHEDULE OF CONVERSION DEBT	The following table provides a summary of the Company’s 2021 note conversions during the nine-month period ending September 30, 2022: SCHEDULE OF CONVERSION DEBT Three Months Ended Shares Weighted Average Conversion Value March 31, 2022 235,428 $ 27.07 $ 6,372,700 June 30, 2022 274,058 $ 17.61 4,826,053 September 30, 2022 339,854 $ 6.84 2,323,081 Total 849,340 $ 13,521,834
2022 Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERSION DEBT	The following table provides a summary of the Company’s 2022 Notes conversions during the nine-month period ending September 30, 2022: SCHEDULE OF CONVERSION DEBT Three Months Ended Shares Weighted Average Conversion Price Conversion Value September 30, 2022 88,584 $ 4.04 $ 357,701 Total 88,584 $ 357,701

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
SCHEDULE OF OUTSTANDING WARRANT	On September 30, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 945,063 $ 200.00 230.00 LACQ warrants Equity (b) 55,306 $ 4.04 Share subscription facility Equity (c) 18,058 $ 15.60 2021 Notes Liability (d) 36,116 $ 15.60 2021 Notes Liability (e) 233,394 $ 14.17 2022 Notes Liability (f) 233,394 $ 14.17 2022 Notes Liability 1,521,331 a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 945,063 200.00 230.00 June 30, 2026 500,000 445,063 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 25,000 230.00 200.00 56,590 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 55,306 three 200.20 289.80 11.6 On December 28, 2021, January 3, 2022, February 1, 2022, March 1, 2022, May 2, 2022,June 1, 2022, July 1, 2022, August 10, 2022, September 20, 2022 and September 29, 2022 the exercise price of the warrants adjusted to $ 90.00 56.60 31.60 19.20 18.80 9.20 8.00 7.00 4.60 4.00 c) On September 24, 2021, the Company issued 18,058 152.60 September 23, 2026 15.60 d) On November 5, 2021, the Company issued 36,116 152.60 November 4, 2026 15.60 e) On July 1, 2022, the Company issued 233,394 14.17 June 29, 2027 f) On August 9, 2022, the Company issued 233,394 14.17 August 8, 2027
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS	The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (a) LACQ (b) Share (b) Share Stock price $ 289.80 $289.80 $ 4.80 85.80 Exercise price $ 200.00 230.00 $200.20 $ 4.00 90.00 Expected term (years) 3.00 3.00 1.76 2.49 Volatility 110.0 % 110.0 108.2 125.3 Risk free rate 0.5 % 0.5 1.0 4.2 (c) Liability (c) Liability (d) Liability (d) Liability Stock price $ 89.80 $ 4.30 $ 45.00 $ 4.30 Exercise price $ 152.60 $ 15.60 $ 152.60 $ 15.60 Expected term (years) 5.00 4.00 5.00 4.10 Volatility 94.1 % 116.1 % 94.1 % 114.9 % Risk free rate 1.0 % 4.1 % 1.0 % 4.1 % (e) Liability (e) Liability (f) Liability (f) Liability Stock price $ 11.40 $ 4.40 $ 10.60 $ 4.40 Exercise price $ 14.20 $ 14.20 $ 14.20 $ 14.20 Expected term (years) 5.00 4.75 5.00 4.86 Volatility 98.9 % 109.4 % 102.8 % 108.3 % Risk free rate 2.9 % 4.1 % 3.0 % 4.1 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining Intrinsic value Outstanding at December 31, 2021 222,191 $ 48.00 6.00 $ 10,207,306 Granted 114,550 77.30 7.63 - Exercised - - - - Expired / Forfeited (10,000 ) 21.40 - - Outstanding at September 30, 2022 326,741 59.13 6.57 - Exercisable at September 30, 2022 284,014 62.03 6.15 - Vested and expected to vest 326,741 59.13 6.57 -
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS	The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Nine Months Ended September 30, 2022 Stock price $ 8.60 34.00 Exercise price $ 8.5 125.60 Expected stock price volatility 76.61 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52 3.14 % Expected dividend yield 0 %
SCHEDULE OF RESTRICTED STOCK UNITS	The following table summarizes the Company’s restricted stock units activity during the nine months ended September 30, 2022: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weight average fair value Outstanding at December 31, 2021 - $ - Granted 61,367 23.02 Released (34,867 ) 26.25 Cancelled (10,000 ) - Outstanding at September 30, 2022 16,500 10.63
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE	The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE September 30, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 343,241 Awards available for future grant under 2021 Omnibus Incentive Plan 44,095 2022 Notes outstanding 754,149 Warrants outstanding 1,521,331 Total shares of common stock reserved for future issuance 2,662,816

ORGANIZATION AND PRINCIPAL AC_2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares	Sep. 30, 2022	Aug. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021	Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]
Common stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Debt instrument, conversion price	$ 0.06585
Common stock, shares authorized	250,000,000		150,000,000	150,000,000
Preferred stock, shares authorized	1,500,000		1,500,000	1,500,000
Preferred stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Former Ensysce [Member]
Restructuring Cost and Reserve [Line Items]
Debt instrument, conversion price					$ 0.06585
Ownership percentage					71.80%
Covistat, Inc., [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage		79.20%
Covistat, Inc., [Member] | Key Personnel [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage		19.80%
Covistat, Inc., [Member] | Unrelated Party [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage		1%
Former Ensysce [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, par value					$ 0.0001
Covistat, Inc., [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, par value						$ 0.001
Common stock, shares authorized						1,000,000
Preferred stock, shares authorized						100,000
Preferred stock, par value						$ 0.001

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)

1 Months Ended

9 Months Ended

Oct. 28, 2022

Oct. 28, 2022

Aug. 09, 2022

Jul. 31, 2022

Jun. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Sep. 29, 2022

Sep. 20, 2022

Aug. 10, 2022

Jul. 02, 2022

Jul. 01, 2022

Jun. 01, 2022

May 02, 2022

Mar. 01, 2022

Feb. 01, 2022

Jan. 03, 2022

Dec. 31, 2021

Dec. 28, 2021

Nov. 05, 2021

Sep. 24, 2021

Jul. 02, 2021

Dec. 31, 2020

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Cash

$ 7,800,000

Prepaid expense

$ 1,100,000

Debt Instrument, conversion price

$ 0.06585

Accumulated deficit

$ 105,409,155

$ 85,845,567

Common stock, subscriptions value

$ 60,000,000

Warrants issued shares

233,394

945,063

233,394

36,116

18,058

55,306

Warrant, exercise price

$ 14.17

$ 4

$ 4.60

$ 7

$ 14.17

$ 8

$ 9.20

$ 18.80

$ 19.20

$ 31.60

$ 56.60

$ 90

$ 152.60

$ 152.60

Debt instrument, face amount

8,855,142

$ 14,032,528

Proceeds from issuance of convertible notes

$ 8,480,000

$ 7,533,915

$ 4,549,842

Convertible Note Financing Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Debt instrument, face amount

$ 15,900,000

July 2022 [Member] | Common Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

$ 800,000

January 2023 [Member] | Common Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

$ 400,000

Investor [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants issued shares

55,306

Warrant, exercise price

$ 200.20

Commitment fees

$ 1,200,000

Investor [Member] | First Anniversary [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

800,000

Investor [Member] | 18-Month Anniversary [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

$ 400,000

Subsequent Event [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Reverse stock split

1-for-20 reverse split

1-for-20 reverse split

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	$ 8,586,102	$ 16,799,837
Liability classified warrants	1,414,829	3,303,588
Total	10,000,931	20,103,425
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	8,586,102	16,799,837
Liability classified warrants	1,414,829	3,303,588
Total	$ 10,000,931	$ 20,103,425

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 20,103,425
Additions, net	12,217,371
Conversions	(14,133,750)
Change in fair value	(8,186,115)
Ending balance	10,000,931
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	16,799,837
Additions, net	8,480,000
Conversions	(14,133,750)
Change in fair value	(2,559,985)
Ending balance	8,586,102
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	3,303,588
Additions, net	3,737,371
Conversions
Change in fair value	(5,626,130)
Ending balance	$ 1,414,829

SCHEDULE OF REVENUE RECOGNIZATI

SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Product Information [Line Items]
Total	$ 279,351	$ 1,200,816	$ 1,089,920	$ 1,895,907
MPAR [Member
Product Information [Line Items]
Total	206,290	1,119,312	710,761	1,246,424
OUD [Member]
Product Information [Line Items]
Total	$ 73,061	$ 81,504	$ 379,159	$ 649,483

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss attributable to common stockholders	$ (9,897,612)	$ (17,163,526)	$ (19,563,588)	$ (19,046,801)
Denominator:
Weighted average shares outstanding, basic and diluted	1,928,727	1,212,791	1,666,253	937,764
Net loss per share attributable to common stockholders, basic and diluted	$ (5.13)	$ (14.15)	$ (11.74)	$ (20.31)

SCHEDULE OF WEIGHTED AVERAGE SH

SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,405,539	1,223,156	1,383,082	561,364
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	350,995	222,203	328,538	225,833
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,054,544	1,000,953	1,054,544	335,531

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2019	Aug. 31, 2019	Sep. 30, 2018
Depreciation expense			$ 50		$ 151
Proceeds from issuance of debt	$ 8,500,000					$ 15,900,000
Grants receivable								$ 10,800,000	$ 5,400,000	$ 5,100,000	$ 5,400,000
Unbilled receivable							$ 214,308
Year 1 [Member]
Grants receivable										2,100,000	3,200,000
Contribution of grants											1,100,000
Year 2 [Member]
Grants receivable										$ 3,000,000	$ 2,200,000
Year 3 [Member]
Grants receivable								2,800,000
Year 4 [Member]
Grants receivable								$ 2,800,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development	$ 2,323,473	$ 2,124,008
Prepaid insurance	550,634	733,234
Other prepaid expenses	108,964	74,173
Total prepaid expenses and other current assets	$ 2,983,071	$ 2,931,415

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Share subscription facility commitment fees	$ 400,000	$ 800,000
Accrued research and development	1,186,498	388,997
Bonus accrual	297,224	610,000
Professional fees	203,034	138,086
Accrued scientific advisory board fees	60,032	60,032
Consultant stock compensation expenses		1,342,479
Other accrued liabilities	89,485	67,939
Total accrued expenses and other liabilities	$ 2,236,273	$ 3,407,533

SCHEDULE OF OTHER LONG-TERM LIA

SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Total other long-term liabilities	$ 1,414,829	$ 3,652,790
Share Subscription Facility Commitment Fees [Member]
Total other long-term liabilities		349,202
Liability Classified Warrants [Member]
Total other long-term liabilities	$ 1,414,829	$ 3,303,588

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 29, 2022	Sep. 20, 2022	Aug. 10, 2022	Aug. 09, 2022	Jul. 02, 2022	Jul. 01, 2022	Jun. 01, 2022	May 02, 2022	Mar. 01, 2022	Feb. 01, 2022	Jan. 03, 2022	Dec. 31, 2021	Dec. 28, 2021	Nov. 05, 2021	Sep. 24, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Contractual obligation		$ 25,700,000		$ 25,700,000
Operating lease, payments				35,403
Rent expense		7,939	$ 11,781	23,606	$ 36,058
Warrant, exercise price						$ 4	$ 4.60	$ 7	$ 14.17	$ 14.17	$ 8	$ 9.20	$ 18.80	$ 19.20	$ 31.60	$ 56.60		$ 90	$ 152.60	$ 152.60
Consultant compensation expenses																	$ 1,342,479
Investors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock issuable upon exercise warrants	25,000
Warrant, exercise price	$ 125.60
Shares issued, share based compensation shares	2,500
Stock issued, restricted stock shares	10,000
Vesting period	1 year
Share based payment award, vesting rights, percentage	50%

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Principal balance	$ 8,855,142		$ 14,032,528
Accrued interest	109,424		163,517
Fair value adjustment	(24,825)
Net debt balance	8,939,741		17,189,106
Fair value adjustment			2,993,061
2021 Notes [Member]
Short-Term Debt [Line Items]
Principal balance	379,695		13,647,341
Accrued interest	11,006		159,435
Fair value adjustment
Net debt balance	390,701		16,799,837
Fair value adjustment			2,993,061
2022 Notes [Member]
Short-Term Debt [Line Items]
Principal balance	8,126,667
Accrued interest	93,559
Fair value adjustment	(24,825)
Net debt balance	8,195,401	$ 4,240,000
Fair value adjustment		$ 500,000
Financed Insurance [Member]
Short-Term Debt [Line Items]
Principal balance	348,780		385,187
Accrued interest	4,859		4,082
Fair value adjustment
Net debt balance	$ 353,639		389,269
Fair value adjustment

SCHEDULE OF INTEREST EXPENSE DE

SCHEDULE OF INTEREST EXPENSE DEBT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Stated interest accrual	$ 4,859	$ 24,660	$ 6,864	$ 251,857
Debt discount amortization				945,969
Total	$ 4,859	$ 24,660	$ 6,864	$ 1,197,826

SCHEDULE OF CONVERSION DEBT (De

SCHEDULE OF CONVERSION DEBT (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Conversion price	$ 0.06585
2021 Notes [Member]
Short-Term Debt [Line Items]
Shares	849,340
Conversion price	$ 117.40
Redemption value	$ 13,521,834
2021 Notes [Member] | Note One [Member]
Short-Term Debt [Line Items]
Conversion date	Mar. 31, 2022
Shares	235,428
Conversion price	$ 27.07
Redemption value	$ 6,372,700
2021 Notes [Member] | Note Two [Member]
Short-Term Debt [Line Items]
Conversion date	Jun. 30, 2022
Shares	274,058
Conversion price	$ 17.61
Redemption value	$ 4,826,053
2021 Notes [Member] | Note Three [Member]
Short-Term Debt [Line Items]
Conversion date	Sep. 30, 2022
Shares	339,854
Conversion price	$ 6.84
Redemption value	$ 2,323,081
2022 Notes [Member]
Short-Term Debt [Line Items]
Shares	88,584
Conversion price		$ 10.90
Redemption value	$ 357,701
2022 Notes [Member] | Note One [Member]
Short-Term Debt [Line Items]
Conversion date	Sep. 30, 2022
Shares	88,584
Conversion price	$ 4.04
Redemption value	$ 357,701

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)									1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 09, 2022 USD ($) $ / shares	Aug. 09, 2022 $ / shares	Aug. 08, 2022 $ / shares shares	Jul. 02, 2022 $ / shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($) $ / shares	Nov. 05, 2021 USD ($) $ / shares	Sep. 24, 2021 USD ($) $ / shares	Jul. 31, 2022 USD ($) $ / shares	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2022	Dec. 31, 2021 USD ($)	Sep. 29, 2022 $ / shares	Sep. 20, 2022 $ / shares	Aug. 10, 2022 $ / shares	Jul. 01, 2022 $ / shares shares	Jun. 01, 2022 $ / shares	May 02, 2022 $ / shares	Mar. 01, 2022 $ / shares	Feb. 01, 2022 $ / shares	Jan. 03, 2022 $ / shares	Dec. 28, 2021 $ / shares	Aug. 03, 2021 $ / shares	Jun. 30, 2021 $ / shares
Short-Term Debt [Line Items]
Proceeds from convertible debt	$ 8,480,000											$ 7,533,915	$ 4,549,842
Conversion price | $ / shares										$ 0.06585		$ 0.06585
Notes payable										$ 8,939,741		$ 8,939,741			$ 17,189,106
Cash proceeds from issuance of debt									$ 8,500,000						15,900,000
Original issue discount															2,993,061
Change in fair value of convertible notes										(3,491,513)	$ (1,071,099)	(6,169,929)	(1,071,099)
Conversion of stock amount converted										100,000		100,000
Warrants exercise price | $ / shares	$ 14.17	$ 14.17		$ 14.17			$ 152.60	$ 152.60								$ 4	$ 4.60	$ 7	$ 8	$ 9.20	$ 18.80	$ 19.20	$ 31.60	$ 56.60	$ 90
Financed insurance premiums												399,949	867,300		900,000
Interest expense										4,859	$ 24,660	57,662	$ 1,282,820
Financed Insurance Premiums [Member]
Short-Term Debt [Line Items]
Interest expense										4,589		$ 6,684
Maximum [Member]
Short-Term Debt [Line Items]
Warrants exercise price | $ / shares																										$ 200	$ 230
Minimum [Member]
Short-Term Debt [Line Items]
Warrants exercise price | $ / shares																										$ 230	$ 200
2021 Notes [Member]
Short-Term Debt [Line Items]
Convetible debt							$ 10,600,000	$ 5,300,000
Proceeds from convertible debt							$ 9,400,000	$ 4,600,000
Debt maturity date							Aug. 04, 2023	Jun. 23, 2023
Debt instrument, interest rate												5%
Debt instrument original issue discount												6%
Payments of Debt Issuance Costs												$ 15,900,000
Debt Issuance Costs, Net										1,900,000		1,900,000
Legal Fees												1,000,000
Amortization of Debt Issuance Costs												900,000
Gain loss on fair value of interest rates										45,329		$ 2,700,000
Percentage of cash settlement premium												8%
Interest expense after consideration of conversion										$ 39,847		$ 200,000
Conversion price | $ / shares										$ 117.40		$ 117.40
Debt instrument, convertible, terms of conversion feature												beneficial ownership limitation of 4.99%
Debt instrument, redemption, description												The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $117.40 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $15.60 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder.
Debt instrument, redemption price, percentage												92%
Debt instrument conversion price per share | $ / shares												$ 15.60
Repayments of notes payable												$ 265,812
Convertible debt										$ 5,000,000		5,000,000
Notes payable										390,701		390,701			16,799,837
Original issue discount															$ 2,993,061
Warrants exercise price | $ / shares			$ 15.60																$ 15.60
2021 Notes [Member] | Other Operating Income (Expense) [Member]
Short-Term Debt [Line Items]
Loss on debt conversions										1,400,000		4,000,000
Debt conversions										$ 1,000,000		$ 1,000,000
2021 Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares			15.60							$ 4.60		$ 4.60
Debt instrument, redemption price, percentage												20%
2021 Notes [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares			$ 7							$ 7		$ 7
2022 Notes [Member]
Short-Term Debt [Line Items]
Convetible debt					$ 8,000,000	$ 8,000,000
Debt maturity date		Feb. 07, 2024		Dec. 29, 2023
Conversion price | $ / shares					$ 10.90	$ 10.90
Convertible debt										$ 5,000,000		$ 5,000,000
Notes payable					$ 4,240,000	$ 4,240,000				8,195,401		8,195,401
Cash proceeds from issuance of debt					4,000,000
Initial fair value					12,060,000	12,060,000
Loss on issuance of fair value					3,600,000
Issuance costs					$ 1,100,000
Original issue discount rate					6%
Original issue discount					$ 500,000	$ 500,000
Legal and investment banking fees					$ 600,000
Change in fair value of convertible notes										$ 3,500,000		$ 3,500,000
Common stock average price percentage						0.10
Debt conversion description						The Company may elect to pay all or part of the redemption amount in cash with a premium of eight percent or in conversion shares of common stock based on a conversion price equal to the lesser of (i) the conversion price and (ii) 92% of the average of the three lowest VWAPs (as defined) during the ten consecutive trading days ending on the trading day that is immediately prior to the applicable redemption date, but in no event may the Company pay the redemption amount in conversion shares of common stock unless the conversion price is at least equal to $2.006 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder.
Warrants to purchase common stock | shares			233,395																233,395
Warrants exercise price | $ / shares			$ 14.17						$ 15.60										$ 14.17
Percenatge of premium conversion price			30%																30%
Debt term			5 years
Debt interest rate	6%	6%																	6%
Original issue discount rate percentage	6%	6%																	6%
2022 Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, redemption price, percentage														20%

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANT (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	1,521,331
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	945,063	[1]
Warrant description	LACQ warrants	[1]
Warrant One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 200	[1]
Warrant One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 230	[1]
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	55,306	[2]
Exercise price | $ / shares	$ 4.04	[2]
Warrant description	Share subscription facility	[2]
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	18,058	[3]
Exercise price | $ / shares	$ 15.60	[3]
Warrant description	2021 Notes	[3]
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	36,116	[4]
Exercise price | $ / shares	$ 15.60	[4]
Warrant description	2021 Notes	[4]
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	233,394	[5]
Exercise price | $ / shares	$ 14.17	[5]
Warrant description	2022 Notes	[5]
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	233,394	[6]
Exercise price | $ / shares	$ 14.17	[6]
Warrant description	2022 Notes	[6]
[1]On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 945,063 200.00 230.00 June 30, 2026 500,000 445,063 55,306 three 200.20 289.80 11.6 18,058 152.60 September 23, 2026 15.60 36,116 152.60 November 4, 2026 15.60 233,394 14.17 June 29, 2027 233,394 14.17 August 8, 2027

SCHEDULE OF OUTSTANDING WARRA_2

SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - USD ($)

9 Months Ended

Aug. 03, 2021

Jul. 02, 2021

Jun. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Sep. 29, 2022

Sep. 20, 2022

Aug. 10, 2022

Aug. 09, 2022

Aug. 08, 2022

Jul. 31, 2022

Jul. 02, 2022

Jul. 01, 2022

Jun. 01, 2022

May 02, 2022

Mar. 01, 2022

Feb. 01, 2022

Jan. 03, 2022

Dec. 28, 2021

Nov. 05, 2021

Sep. 24, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

55,306

945,063

233,394

233,394

36,116

18,058

Warrants, exercise price

$ 4

$ 4.60

$ 7

$ 14.17

$ 14.17

$ 8

$ 9.20

$ 18.80

$ 19.20

$ 31.60

$ 56.60

$ 90

$ 152.60

$ 152.60

Warrant expiration date

Jun. 30, 2026

Aug. 08, 2027

Jun. 29, 2027

Nov. 04, 2026

Sep. 23, 2026

Fair value adjustment of warrants

$ 11,565,472

Warrant term

3 years

2022 Notes [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 14.17

$ 15.60

$ 14.17

General and Administrative Expense [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 200.20

Fair value adjustment of warrants

$ 11,600,000

Grant date fair value of warrants price per share

$ 289.80

Subscription Arrangement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

25,000

Subscription Arrangement [Member] | General and Administrative Expense [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Fair value adjustment of warrants

$ 56,590

Public Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of warrant or right, outstanding

500,000

Private Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Remaining of cashless warrant shares

445,063

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 230

$ 200

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 200

$ 230

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)	Sep. 30, 2022 $ / shares	Aug. 09, 2022 $ / shares	Jul. 01, 2022 $ / shares	Nov. 05, 2021 $ / shares	Sep. 24, 2021 $ / shares	Jul. 02, 2021 $ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years						3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	289.80
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	200
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	230
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	110
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.5
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						289.80
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.80
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	85.80
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						200.20
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	90
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years						3 years
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1
Expected term years	1 year 9 months 3 days
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.2
Expected term years	2 years 5 months 26 days
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						110
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	108.2
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	125.3
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						0.5
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		10.60	11.40	45	89.80
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		14.20	14.20	152.60	152.60
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years		5 years	5 years	5 years	5 years
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		102.8	98.9	94.1	94.1
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		3	2.9	1	1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.30
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	15.60
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	116.1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.1
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.30
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	15.60
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 1 month 6 days
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	114.9
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.1
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.40
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	14.20
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 9 months
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	109.4
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.1
Liability Classified Warrants Remeasured3 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.40
Liability Classified Warrants Remeasured3 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	14.20
Liability Classified Warrants Remeasured3 [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 10 months 9 days
Liability Classified Warrants Remeasured3 [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	108.3
Liability Classified Warrants Remeasured3 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.1

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Jun. 30, 2021	Jan. 31, 2021	Sep. 30, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Common stock, shares authorized	150,000,000		250,000,000	150,000,000
Preferred stock, shares authorized	1,500,000		1,500,000	1,500,000
common stock par value	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock par value	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares issued			0	0
Preferred stock, shares outstanding			0	0
Common stock, shares, issued			2,208,446	1,233,148
Common stock, shares outstanding	310,963		2,207,458	1,232,160
Stock issued to settlement of convertible debt	67,899
Stock issued to settlement amount of convertible debt	$ 5.8
Common stock issued to settlement of termination agreement		25,000
Common stock issued to settelment of underwriting costs	6,250
Former Ensysce [Member]
Restructuring Cost and Reserve [Line Items]
common stock par value		$ 0.0001
Common stock, shares, issued	802,679
Stock issued during period shares purchase of assets	988

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance | shares	222,191
Weighted average exercise price. beginning balance	$ 48
Weighted average remaining contractual term, beginning balance	6 years
Aggregate intrinsic value, beginning balance | $	$ 10,207,306
Option outstanding, granted | shares	114,550
Weighted average exercise price, granted	$ 77.30
Weighted average remaining contractual term, grants	7 years 7 months 17 days
Aggregate intrinsic value, granted
Option outstanding, exercised | shares
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised | $
Option outstanding, Expired or Forfeited | shares	(10,000)
Weighted average exercise price, expired / forfeited	$ 21.40
Aggregate intrinsic value, expired or forfeited | $
Option outstanding, ending balance | shares	326,741
Weighted average exercise price, ending balance	$ 59.13
Weighted average remaining contractual term, ending balance	6 years 6 months 25 days
Aggregate intrinsic value, ending balance | $
Option, exercisable | shares	284,014
Weighted average exercise price, exercisable	$ 62.03
Weighted average remaining contractual term, exercisable	6 years 1 month 24 days
Aggregate intrinsic value, beginning balance | $
Option vested or expected to vest | shares	326,741
Weighted average exercise price, vested or expected to vest	$ 59.13
Weighted average remaining contractual term in years, vested and expected to vest	6 years 6 months 25 days
Aggregate intrinsic value, vested or expected to vest | $

SCHEDULE OF SHARE-BASED PAYMENT

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility, minimum	76.61%
Expected stock price volatility, maximum	95.87%
Risk-free interest rate, minimum	1.52%
Risk-free interest rate, maximum	3.14%
Expected dividend rate	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price	$ 8.60
Exercise price	$ 8.5
Expected term (years)	5 years 2 months 8 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price	$ 34
Exercise price	$ 125.60
Expected term (years)	10 years

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units outstanding, beginning balance | shares
Weight average fair value, beginning balance | $ / shares
Restricted stock units, granted | shares	61,367
Weight average fair value, granted | $ / shares	$ 23.02
Restricted stock units, released | shares	(34,867)
Weight average fair value, released | $ / shares	$ 26.25
Restricted stock units, cancelled | shares	(10,000)
Weight average fair value, cancelled | $ / shares
Restricted stock units outstanding, ending balance | shares	16,500
Weight average fair value, ending balance | $ / shares	$ 10.63

SCHEDULE OF COMMON STOCK FUTURE

SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)	Sep. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	2,662,816
Warrant Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	1,521,331
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	343,241
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	44,095
Share-Based Payment Arrangement, Option [Member] | 2022 Notes Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	754,149

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jan. 26, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	326,741		326,741			222,191
Stock reserved for future issuance	2,662,816		2,662,816
Number of restricted stock granted			114,550
Exercise price per share vested	$ 59.13		$ 59.13
Weighted-average fair value per share , grant			$ 19.24
Unrecognized stock based compensation	$ 605,868		$ 605,868
Weighted average period			1 year 5 months 1 day
Board of Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock granted			114,550
Board of Members [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period			0 years
Exercise price per share vested	$ 8.50		$ 8.50
Board of Members [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period			4 years
Exercise price per share vested	$ 125.60		$ 125.60
General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 128,357	$ 24,833	$ 731,126	$ 105,026
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 28,791	$ 0	$ 124,034	$ 0
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	221,191		221,191
Stock reserved for future issuance	50,000		50,000		150,000

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Oct. 31, 2022	Jul. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share-Based Payment Arrangement, Noncash Expense					$ 855,160	$ 105,026
Stock Issued During Period, Value, New Issues
Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock Issued During Period, Shares, New Issues	46,062
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share-Based Payment Arrangement, Noncash Expense				$ 3,584		$ 43,898
Chief Executive Officer And Board Member [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock Issued During Period, Shares, New Issues		46,062
Stock Issued During Period, Value, New Issues		$ 800,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Oct. 28, 2022	Oct. 28, 2022	Oct. 11, 2022	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Number of common stock issued on conversion					$ 4,074,063	$ 17,868,097	$ 5,696,703
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	1-for-20 reverse split	1-for-20 reverse split
Subsequent Event [Member] | 2021 Notes [Member]
Subsequent Event [Line Items]
Remaining debt principal and accrued interest outstanding			$ 390,701
Subsequent Event [Member] | 2022 Notes [Member]
Subsequent Event [Line Items]
Number of common stock issued on conversion, shares				573,944
Number of common stock issued on conversion				$ 2,100,000